Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Immunoregulatory role of saliva polymeric IgA1 in the pathogenesis of primary Sjögren’s Syndrome

Award Number: R03DE030990
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/02/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2024

Group Awards By:

View Award Description

Immunoregulatory role of saliva polymeric IgA1 in the pathogenesis of primary Sjögren’s Syndrome - PROJECT SUMMARY/ABSTRACT To date, the pathogenesis of primary Sjögren’s Syndrome (pSS) is not well understood resulting in a 3 to 6 year delayed initial diagnosis. Serum anti-Ro/SSA autoantibodies and biopsy focus score are two key classification criteria of pSS by the 2016 ACR-EULAR1. Literature demonstrated that biopsy focus score is positively associated with the area of minor salivary gland fibrosis, common consequence of tissue damage and inflammation2,3. It is unclear whether tissue-resident lymphocyte infiltration or anti-Ro/SSA autoantibodies initiated autoimmune tissue destruction and orchestrated pSS disease progression. This proposal is to investigate the crosstalk between salivary anti-Ro52/SSA and salivary gland tissue destruction. We have developed a saliva-based electrochemical assay, electric field-induced release and measurement (EFIRM), that can screen, earlier detect, risk assess onset of pSS, alternative to the current ELISA blood-based serology assay. Preliminary data demonstrated: 1) EFIRM can directly detect and quantify salivary anti- Ro52/SSA autoantibodies in pSS patients; 2) Salivary and serum anti-Ro/SSA are correlated in pSS and Sicca patients; 3) Salivary anti-Ro52/SSA IgA1 correlate to salivary gland focus scores. IgA exists in two isotypes, IgA1 and IgA2, and IgA1 can further be subdivided into monomeric (mIgA1) and polymeric (pIgA1) subclasses4,5. Human serum IgA1 mostly exists as monomeric form (85-90%) whereas saliva secretory IgA1 are predominantly polymeric form (90-95%) secreted by polymeric Ig receptor (pIgR). Monomeric and polymeric IgA1 are structurally different due to the presence of galactose in the mIgA1, and absence in the pIgA14,6,7. The presence of galactose in mIgA1 can be detected using the galactose-specific legume lectin, Erythrina cristagalli lectin (ECL)8 whereas pIgA1 can be detected using the N-acetylgalactosamine binding lectin, Helix pomatia agglutinin (HPA)9. In addition to structural differences, mIgA1 and pIgA1 also exhibit differential immunoregulatory roles as immune suppressor5,7 and inducer10 respectively. We hypothesize that salivary pIgA1 anti-Ro52/SSA in pSS patients is associated with salivary gland tissue destruction, measured by biopsy focus score. Two Specific Aims are proposed to test this hypothesis. Aim 1 is to develop saliva-based anti-Ro52 mIgA1 and pIgA1 immunoassays. Aim 2 is to measure anti-Ro52 mIgA1 and pIgA1 in saliva of pSS, Sicca, and control subjects to investigate the correlation of saliva pIgA1 to salivary gland fibrosis and destruction. In future research plan, we will investigate the crosstalk between salivary pIgA1 anti-Ro52/SSA and tissue-resident immune T helper 17 cells12–14. Our studies are intended to determine the role of salivary autoantibody, anti-Ro52/SSA polymeric IgA1, in the context of salivary gland destruction in pSS patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Oral Diseases and Disorders Research	000	2	2/6/2025	NON-COMPETING CONTINUATION	$0
2025	2022	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Oral Diseases and Disorders Research	001	2	4/7/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $156,000 )
2022	2022	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Oral Diseases and Disorders Research	000	2	6/24/2022	NON-COMPETING CONTINUATION	$156,000
														Subtotal = $156,000

Issue Date FY: 2021 ( Subtotal = $156,000 )
2021	2021	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Oral Diseases and Disorders Research	000	1	7/2/2021	NEW	$156,000
														Subtotal = $156,000

Grand Total All Awards = $312,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immunoregulatory role of saliva polymeric IgA1 in the pathogenesis of primary Sjögren’s Syndrome

Award Number: R03DE030990

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/02/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer